AZ unveils monster US$80B target

Overnight AstraZeneca unveiled its "bold ambition" to deliver US$80 billion in total revenue by the end of decade with the launch of 20 new medicines.

In announcing "the new era of growth" AstraZeneca's CEO, Pascal Soriot said many of the products have "the potential to generate more than US$5 million in peak year revenues".

"In 2023 we delivered the ambitious $45 billion revenue goal set a decade ago," he said.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here